Dementia

Clinical Framework for Dementia in Primary Care

Dementia is a clinical syndrome characterized by progressive cognitive decline that interferes with independent functioning. For the Family Nurse Practitioner (FNP), recognizing early signs, differentiating dementia from delirium and depression, and managing comorbid conditions are essential skills. Dementia is a high-yield topic on FNP board exams and a common presenting complaint in primary care. [1]

This section covers:

  • Key definitions and subtypes
  • Diagnostic criteria and assessment tools
  • Pharmacologic and non-pharmacologic management
  • Safety considerations and caregiver support

Distinguishing Dementia Subtypes and Mimics

Dementia vs. Delirium vs. Depression (3 Ds)

  • Dementia: Chronic, progressive, insidious onset; global cognitive decline; no alteration in consciousness (until late stages). [2]
  • Delirium: Acute, fluctuating, reversible; caused by medical illness or medication; altered consciousness and inattention. [2]
  • Depression (pseudodementia): Depressed mood, anhedonia; cognitive complaints that improve with treatment of depression; often presents in the elderly with loss of interest. [3]

Common Dementia Subtypes

  • Alzheimer disease (AD): Most common (60–80%); insidious onset; early impairment in short-term memory; later language, visuospatial deficits. [4]
  • Vascular dementia (VaD): Stepwise decline; history of stroke or cardiovascular disease; focal neurological signs; executive function affected early. [5]
  • Lewy body dementia (LBD): Fluctuating cognition; visual hallucinations; parkinsonism; REM sleep behavior disorder. [6]
  • Frontotemporal dementia (FTD): Early behavioral changes (disinhibition, apathy) or language deficits; memory relatively spared early; onset usually before age 65. [7]

Mild Cognitive Impairment (MCI)

  • Objective cognitive decline not interfering with daily activities
  • High risk of progression to dementia (10–15% per year) [8]
  • FNP should monitor closely and address risk factors

Diagnostic Workup and Screening Strategies

Screening and Case-Finding

  • When to screen: Any patient ≥65 with subjective cognitive complaints, or high risk (e.g., vascular disease, family history). [9]
  • Tools:
    • Mini-Cog (3-item recall + clock draw) – quick, valid [9]
    • Montreal Cognitive Assessment (MoCA) – more sensitive for MCI [10]
    • Mini-Mental State Exam (MMSE) – widely used, but may have copyright/performance issues

Diagnostic Workup (Algorithm)

  1. History – onset, progression, impact on function; collateral from family
  2. Medication review – anticholinergics, sedatives, opioids can mimic dementia
  3. Physical and neurological exam – focal signs, rigidity, tremor, gait disturbance
  4. Laboratory studies – CBC, CMP, TSH, B12, syphilis serology, HIV in at-risk patients [8]
  5. Neuroimaging – noncontrast head CT or MRI to rule out structural causes (tumor, subdural hematoma, normal pressure hydrocephalus) [8]
  6. Formal neuropsychological testing if diagnosis uncertain or atypical features

Comparative Clinical Profiles by Subtype

Clinical Features by Dementia Subtype
Feature Alzheimer disease Vascular dementia Lewy body dementia Frontotemporal dementia
Early memory loss Prominent Variable May be less prominent Usually spared early
Motor features Late Early gait problems, focal weakness Parkinsonism (rigidity, bradykinesia) May have motor neuron disease
Hallucinations Late, if present Rare Early, visual, well-formed Rare
Fluctuations No Stepwise decline Prominent No
Behavioral changes Late apathy, agitation Depression common REM sleep behavior disorder Early disinhibition, loss of empathy

Staging Severity and Functional Impact

Dementia Severity Staging

  • Mild (early): Forgets recent events; still independent in basic ADLs; may need assistance with complex tasks (finances, driving)
  • Moderate: Needs help with instrumental ADLs; behavioral symptoms common (wandering, aggression, sleep disturbance)
  • Severe (late): Dependent for all ADLs; nonverbal; requires full-time care

Functional Assessment

  • Basic ADLs: Bathing, dressing, toileting, eating, mobility – affected in moderate-to-severe dementia
  • Instrumental ADLs (IADLs): Managing finances, medications, transportation, telephone, shopping – impaired early

Behavioral and Psychological Symptoms of Dementia (BPSD)

  • Common: agitation, aggression, psychosis (delusions, hallucinations), depression, apathy, wandering
  • Must assess triggers (pain, infection, environmental change) before pharmacologic intervention [11]

Therapeutic Strategies: Non-Pharmacologic and Pharmacologic

Non-Pharmacologic (First-Line)

  • Environmental modifications: Simplify routines, secure environment (wandering prevention), fall-proof home
  • Caregiver education and support: Refer to Alzheimer's Association, support groups, respite care [11]
  • Cognitive stimulation: Structured activities, music therapy, pet therapy
  • Behavioral approach: Identify antecedents, redirect, validate feelings, avoid confrontation

Pharmacologic Management

  • Cholinesterase inhibitors (donepezil, rivastigmine, galantamine): Standard for mild-to-moderate Alzheimer disease. Can slow decline but not curative. Common side effects: nausea, diarrhea, bradycardia. [12]
  • Memantine (NMDA antagonist): Used for moderate-to-severe Alzheimer disease, often in combination with donepezil. [12]
  • Vascular dementia: No FDA-approved medications; control vascular risk factors (hypertension, diabetes, hyperlipidemia). [5]
  • LBD: Cholinesterase inhibitors may help cognition and hallucinations; antipsychotics should be used with extreme caution (neuroleptic sensitivity). [6]
  • BPSD pharmacotherapy:
    • First-line: Non-pharmacologic approaches
    • Second-line (severe, dangerous, or distressing): Atypical antipsychotics (risperidone, olanzapine, quetiapine) in lowest effective dose, shortest duration. [11]
    • Warning: Antipsychotics increase mortality in elderly with dementia (black box warning). [13]
    • Antidepressants (SSRIs): For depression or agitation (e.g., citalopram)

Safety Planning and Risk Reduction Measures

  • Driving assessment: Most patients with dementia will need to stop driving eventually; report to DMV if required by state law.
  • Fall risk: Especially in moderate-to-severe disease, LBD, and vascular dementia; home safety evaluation, gait aid, de-clutter.
  • Wandering: Enroll in Safe Return/MedicAlert program; door alarms; child-safety locks.
  • Medication safety: Pill organizers, caregivers to monitor, avoid anticholinergics and benzodiazepines when possible.
  • Elder abuse/neglect: Screen caregivers for burnout; report suspected abuse.
  • Advance care planning: Initiate early while patient has capacity; document healthcare proxy, living will.

Exam-Focused Clinical Distinctions and Highlights

  • Memorize the 3 Ds (Dementia, Delirium, Depression) – they are frequently compared.
  • Know that Alzheimer disease typically presents with early short-term memory loss; FTD presents with early personality/behavior changes.
  • Lewy body dementia is distinguished by visual hallucinations and fluctuating cognition; extreme sensitivity to antipsychotics is a classic exam point.
  • The cause of reversible dementia includes: B12 deficiency, hypothyroidism, normal pressure hydrocephalus (NPH – triad: gait disturbance, urinary incontinence, cognitive decline), subdural hematoma, depression.
  • Non-pharmacologic interventions are first line for BPSD – exam scenarios often test this.
  • Remember the black box warning for antipsychotics in elderly with dementia (increased cardiovascular/cerebrovascular events).
  • The Mini-Cog is the preferred quick screening tool for primary care.
  • For vascular dementia, focus on prevention – controlling hypertension, diabetes, and statin use reduces progression.
  • Anticholinergic burden (e.g., diphenhydramine, oxybutynin) can cause or worsen cognitive decline – this is a high-yield exam question.

References & Sources

  1. Alzheimer's Association. 2025 Alzheimer's disease facts and figures. Alzheimers Dement. 2025;21(1):e091211. https://doi.org/10.1002/alz.091211
  2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed, text revision. Washington, DC: American Psychiatric Publishing; 2022. https://doi.org/10.1176/appi.books.9780890425787
  3. Alexopoulos GS. Depression in the elderly. Lancet. 2005;365(9475):1961-1970. https://doi.org/10.1016/S0140-6736(05)66665-2
  4. Scheltens P, Blennow K, Breteler MMB, et al. Alzheimer's disease. Lancet. 2016;388(10043):505-517. https://doi.org/10.1016/S0140-6736(15)01124-1
  5. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88-100. https://doi.org/10.1212/WNL.0000000000004058
  6. Bang J, Spina S, Miller BL. Frontotemporal dementia. Lancet. 2015;386(10004):1672-1682. https://doi.org/10.1016/S0140-6736(15)00461-4
  7. Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: Mild cognitive impairment. Neurology. 2018;90(3):126-135. https://doi.org/10.1212/WNL.0000000000004826
  8. Borson S, Scanlan J, Brush M, Vitaliano P, Dokmak A. The mini-cog: a cognitive 'vital signs' measure for dementia screening in multi-lingual elderly. Int J Geriatr Psychiatry. 2000;15(11):1021-1027. https://doi.org/10.1002/1099-1166(200011)15:11<1021::AID-GPS234>3.0.CO;2-6
  9. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699. https://doi.org/10.1111/j.1532-5415.2005.53221.x
  10. Gitlin LN, Kales HC, Lyketsos CG. Nonpharmacologic management of behavioral symptoms in dementia. JAMA. 2012;308(19):2020-2029. https://doi.org/10.1001/jama.2012.36918
  11. Howard R, McShane R, Lindesay J, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med. 2012;366(10):893-903. https://doi.org/10.1056/NEJMoa1106668
  12. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934-1943. https://doi.org/10.1001/jama.294.15.1934

Ready to test your knowledge?

Master the core responsibilities, scope of practice, and limitations for the Family Nurse Practitioner exam.

Start Practice Questions
Previous Topic Next Topic